Grim-Score Variations Predict Outcome In Metastatic Nsclc Patients Treated With First-Line Pembrolizumab

Prompt identification of metastatic non-small cell lung cancer patients (NSCLC) who benefit from first-line pembrolizumab is crucial in clinical practice. The Gustave Roussy Immune Score (GRIm-score) takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) and its prognostic score has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the predictive value of baseline GRIm-score (GRImT0), we separately investigated two cohorts of metastatic NSCLC patients treated with first-line pembrolizumab immunotherapy or chemotherapy (CHT).